The second case reports a 72-year-old PCa patient (ISUP Grade Group 5) who had significant PSA progression (22.6 ng/mL and 47.9 ng/mL, respectively) despite eight cycles of chemotherapy and enzalutamide treatment. Here, KLK3 is linked to posterior cortical atrophy.